Oridonin enhances TRAIL-induced apoptosis through GALNT14-mediated DR5 glycosylation.
作者： Mi-Yeon Jeon , Seung Un Seo , Seon Min Woo , Kyoung-jin Min , Hee Sun Byun
DOI: 10.1016/J.BIOCHI.2019.07.015
关键词:
摘要: Oridonin is a diterpenoid isolated from the Rabdosia rubescens and has multiple biological effects, such as anti-inflammation anti-tumor activities. In present study, we revealed that sensitizing effect of oridonin on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in several cancer cells, but not normal cells. enhanced death-signaling inducing complexes (DISC) formation DR5 glycosylation without affecting expression downstream intracellular apoptosis-related proteins. upregulated peptidyl O-glycosyltransferase GALNT14 dose- time-dependent manner. Knockdown by siRNA Endo H treatment reduced oridonin-induced glycosylation. Furthermore, with inhibitor (benzyl-α-GalNAc) blocked plus TRAIL-induced apoptosis. Collectively, our results suggest contributes to apoptotic cell death
sci-hub.se 参考文章(25)
Zi-Zhen Xu, Wan-Bin Fu, Zhen Jin, Pei Guo, Wen-Fang Wang, Jun-Min Li, Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma. Leukemia & Lymphoma. ,vol. 57, pp. 888- 898 ,(2016) , 10.3109/10428194.2015.1061127
Shengpeng Wang, Zhangfeng Zhong, Jianbo Wan, Wen Tan, Guosheng Wu, Meiwan Chen, Yitao Wang, Oridonin Induces Apoptosis, Inhibits Migration and Invasion on Highly-Metastatic Human Breast Cancer Cells The American Journal of Chinese Medicine. ,vol. 41, pp. 177- 196 ,(2013) , 10.1142/S0192415X13500134
Jae J. Song, Miroslaw Jerzy Szczepanski, So Young Kim, Joo-Hang Kim, Jee Young An, Yong Tae Kwon, Marco A. Alcala, David L. Bartlett, Yong J. Lee, c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance Cellular Signalling. ,vol. 22, pp. 553- 563 ,(2010) , 10.1016/J.CELLSIG.2009.11.012
Kenneth L. Rock, Colette Gramm, Lisa Rothstein, Karen Clark, Ross Stein, Lawrence Dick, Daniel Hwang, Alfred L. Goldberg, Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules Cell. ,vol. 78, pp. 761- 771 ,(1994) , 10.1016/S0092-8674(94)90462-6
Tze-chen Hsieh, E. Kithsiri Wijeratne, Jing-yu Liang, A. Leslie Gunatilaka, Joseph M. Wu, Differential control of growth, cell cycle progression, and expression of NF-κB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens Biochemical and Biophysical Research Communications. ,vol. 337, pp. 224- 231 ,(2005) , 10.1016/J.BBRC.2005.09.040
Klaus W Wagner, Elizabeth A Punnoose, Thomas Januario, David A Lawrence, Robert M Pitti, Kate Lancaster, Dori Lee, Melissa von Goetz, Sharon Fong Yee, Klara Totpal, Ling Huw, Viswanatham Katta, Guy Cavet, Sarah G Hymowitz, Lukas Amler, Avi Ashkenazi, Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL Nature Medicine. ,vol. 13, pp. 1070- 1077 ,(2007) , 10.1038/NM1627
Julianne D. Twomey, Su-Ryun Kim, Liqun Zhao, William P. Bozza, Baolin Zhang, Spatial dynamics of TRAIL death receptors in cancer cells. Drug Resistance Updates. ,vol. 19, pp. 13- 21 ,(2015) , 10.1016/J.DRUP.2015.02.001
Grant D. Stewart, Fiach C. O'Mahony, Thomas Powles, Antony C. P. Riddick, David J. Harrison, Dana Faratian, What can molecular pathology contribute to the management of renal cell carcinoma? Nature Reviews Urology. ,vol. 8, pp. 255- 265 ,(2011) , 10.1038/NRUROL.2011.43
Dana Westphal, Grant Dewson, Peter E. Czabotar, Ruth M. Kluck, Molecular biology of Bax and Bak activation and action Biochimica et Biophysica Acta. ,vol. 1813, pp. 521- 531 ,(2011) , 10.1016/J.BBAMCR.2010.12.019
CHUN-MEI REN, YANG LI, QIAN-ZHAO CHEN, YU-HUA ZENG, YING SHAO, QIU-XIANG WU, SHUANG-XUE YUAN, JUN-QIN YANG, YU YU, KE WU, BAI-CHENG HE, WEN-JUAN SUN, Oridonin inhibits the proliferation of human colon cancer cells by upregulating BMP7 to activate p38 MAPK Oncology Reports. ,vol. 35, pp. 2691- 2698 ,(2016) , 10.3892/OR.2016.4654